Rett Syndrome: Crossing the Threshold to Clinical Translation

[1]  N. Picard,et al.  Chronic Administration of the N-Methyl-D-Aspartate Receptor Antagonist Ketamine Improves Rett Syndrome Phenotype , 2016, Biological Psychiatry.

[2]  M. Sceniak,et al.  Mechanisms of Functional Hypoconnectivity in the Medial Prefrontal Cortex of Mecp2 Null Mice. , 2016, Cerebral cortex.

[3]  Gerald Schwank,et al.  Advances in therapeutic CRISPR/Cas9 genome editing. , 2016, Translational research : the journal of laboratory and clinical medicine.

[4]  H. Zoghbi,et al.  MECP2 disorders: from the clinic to mice and back. , 2015, The Journal of clinical investigation.

[5]  P. Lindberg,et al.  Communication intervention in Rett syndrome: a survey of speech language pathologists in Swedish health services , 2015, Disability and rehabilitation.

[6]  Y. Blat,et al.  Drug Discovery of Therapies for Duchenne Muscular Dystrophy , 2015, Journal of biomolecular screening.

[7]  Wei Li,et al.  MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome , 2015, Proceedings of the National Academy of Sciences.

[8]  S. Pati,et al.  Rett Syndrome: Reaching for Clinical Trials , 2015, Neurotherapeutics.

[9]  Lisa V. Hampson,et al.  Elicitation of Expert Prior Opinion: Application to the MYPAN Trial in Childhood Polyarteritis Nodosa , 2015, Pediatric Rheumatology.

[10]  Harrison W. Gabel,et al.  Disruption of DNA methylation-dependent long gene repression in Rett syndrome , 2015, Nature.

[11]  A. Bird,et al.  Rett syndrome: a complex disorder with simple roots , 2015, Nature Reviews Genetics.

[12]  Wei Li,et al.  Excitation/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice , 2015, Hippocampus.

[13]  J. Blay,et al.  Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative , 2015, European journal of cancer.

[14]  M. Banasr,et al.  BDNF Release Is Required for the Behavioral Actions of Ketamine , 2014, The international journal of neuropsychopharmacology.

[15]  Tianlin Cheng,et al.  Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity , 2014, Nature Communications.

[16]  D. Bedwell,et al.  Therapeutics based on stop codon readthrough. , 2014, Annual review of genomics and human genetics.

[17]  Manel Esteller,et al.  MeCP2: the long trip from a chromatin protein to neurological disorders. , 2014, Trends in molecular medicine.

[18]  Michael R. Green,et al.  Genetic and pharmacological reactivation of the mammalian inactive X chromosome , 2014, Proceedings of the National Academy of Sciences.

[19]  Hye-Seung Lee,et al.  Developmental delay in Rett syndrome: data from the natural history study , 2014, Journal of Neurodevelopmental Disorders.

[20]  H. Zoghbi,et al.  Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice , 2014, eLife.

[21]  P. Williamson,et al.  Methodology of clinical trials for rare diseases. , 2014, Best practice & research. Clinical rheumatology.

[22]  Heather M. O'Leary,et al.  Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome , 2014, Proceedings of the National Academy of Sciences.

[23]  Z. Qiu,et al.  MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. , 2014, Developmental cell.

[24]  A. Kesselheim,et al.  Strategies for Postmarketing Surveillance of Drugs for Rare Diseases , 2014, Clinical pharmacology and therapeutics.

[25]  T. Durand,et al.  Effects of ω-3 PUFAs Supplementation on Myocardial Function and Oxidative Stress Markers in Typical Rett Syndrome , 2014, Mediators of inflammation.

[26]  W. Kaufmann,et al.  Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome , 2014, Journal of Medical Genetics.

[27]  Guoping Fan,et al.  Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain , 2013, Nature Neuroscience.

[28]  J. Ramirez,et al.  Breathing challenges in Rett Syndrome: Lessons learned from humans and animal models , 2013, Respiratory Physiology & Neurobiology.

[29]  David A. Orlando,et al.  Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. , 2013, Cell stem cell.

[30]  N. Yonemoto,et al.  Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients , 2013, Journal of Neurology.

[31]  A. Bird,et al.  Systemic Delivery of MeCP2 Rescues Behavioral and Cellular Deficits in Female Mouse Models of Rett Syndrome , 2013, The Journal of Neuroscience.

[32]  Kairong Cui,et al.  Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition , 2013, Cell Research.

[33]  A. Bird,et al.  Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor , 2013, Nature Neuroscience.

[34]  R. Duman,et al.  Activation of Mammalian Target of Rapamycin and Synaptogenesis: Role in the Actions of Rapid-Acting Antidepressants , 2013, Biological Psychiatry.

[35]  L. Ricceri,et al.  Rett syndrome treatment in mouse models: Searching for effective targets and strategies , 2013, Neuropharmacology.

[36]  F. Lienert,et al.  Methylation-Dependent and -Independent Genomic Targeting Principles of the MBD Protein Family , 2013, Cell.

[37]  S. Durand,et al.  NMDA Receptor Regulation Prevents Regression of Visual Cortical Function in the Absence of Mecp2 , 2012, Neuron.

[38]  E. Kavalali,et al.  Synaptic mechanisms underlying rapid antidepressant action of ketamine. , 2012, The American journal of psychiatry.

[39]  Rodney C. Samaco,et al.  Preclinical research in Rett syndrome: setting the foundation for translational success , 2012, Disease Models & Mechanisms.

[40]  D. Katz,et al.  Brain Activity Mapping in Mecp2 Mutant Mice Reveals Functional Deficits in Forebrain Circuits, Including Key Nodes in the Default Mode Network, that are Reversed with Ketamine Treatment , 2012, The Journal of Neuroscience.

[41]  G. Mandel,et al.  Astrocytes conspire with neurons during progression of neurological disease , 2012, Current Opinion in Neurobiology.

[42]  A. Bird,et al.  Disease Modeling Using Embryonic Stem Cells: MeCP2 Regulates Nuclear Size and RNA Synthesis in Neurons , 2012, Stem cells.

[43]  S. Nelson,et al.  A Critical and Cell-Autonomous Role for MeCP2 in Synaptic Scaling Up , 2012, The Journal of Neuroscience.

[44]  A. Bird,et al.  Postnatal inactivation reveals enhanced requirement for MeCP2 at distinct age windows. , 2012, Human molecular genetics.

[45]  J. Neul.  The relationship of Rett syndrome and MECP2 disorders to autism , 2012, Dialogues in clinical neuroscience.

[46]  Hye-Seung Lee,et al.  Gastrointestinal and Nutritional Problems Occur Frequently Throughout Life in Girls and Women With Rett Syndrome , 2012, Journal of pediatric gastroenterology and nutrition.

[47]  U. Bonuccelli,et al.  IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients , 2012, Autism research and treatment.

[48]  M. D'Esposito,et al.  Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil , 2012, Genes & Nutrition.

[49]  M. Durán,et al.  Folinic Acid Supplementation in Rett Syndrome Patients Does Not Influence the Course of the Disease: A Randomized Study , 2012, Journal of child neurology.

[50]  C. Wong,et al.  Evolution and roles of stanniocalcin , 2012, Molecular and Cellular Endocrinology.

[51]  S. Cobb,et al.  Rett syndrome: from bed to bench. , 2011, Pediatrics and neonatology.

[52]  G. Shepherd,et al.  Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met , 2011, Current Opinion in Neurobiology.

[53]  Jian Jin,et al.  Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons , 2011, Nature.

[54]  S. Cobb,et al.  MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. , 2011, The Biochemical journal.

[55]  M. D'Esposito,et al.  F₄-neuroprostanes mediate neurological severity in Rett syndrome. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[56]  Rodney C. Samaco,et al.  Adult Neural Function Requires MeCP2 , 2011, Science.

[57]  G. Valacchi,et al.  Oxidative stress in Rett syndrome: Natural history, genotype, and variants , 2011, Redox report : communications in free radical research.

[58]  D. Dunkler,et al.  Effects of Creatine Supplementation in Rett Syndrome: A Randomized, Placebo-Controlled Trial , 2011, Journal of developmental and behavioral pediatrics : JDBP.

[59]  S. Ojeda,et al.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  A. Bird,et al.  CpG islands and the regulation of transcription. , 2011, Genes & development.

[61]  M. Durán,et al.  Clinical and Electroencephalographic Effects of Folinic Acid Treatment in Rett Syndrome Patients , 2011, Journal of child neurology.

[62]  M. Giustetto,et al.  Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. , 2011, Human molecular genetics.

[63]  P. Huppke,et al.  Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model , 2010, Journal of Molecular Medicine.

[64]  J. Paton,et al.  Correction of respiratory disorders in a mouse model of Rett syndrome , 2010, Proceedings of the National Academy of Sciences.

[65]  Lydia Wood,et al.  Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in a mutant mouse model of Rett syndrome , 2010, Neurobiology of Disease.

[66]  D. Kunze,et al.  Exogenous Brain-Derived Neurotrophic Factor Rescues Synaptic Dysfunction in Mecp2-Null Mice , 2010, The Journal of Neuroscience.

[67]  S. Skinner,et al.  Epilepsy and the natural history of Rett syndrome , 2010, Neurology.

[68]  Robert S. Illingworth,et al.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. , 2010, Molecular cell.

[69]  Rodney C. Samaco,et al.  Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities , 2009, Proceedings of the National Academy of Sciences.

[70]  S. Nelson,et al.  Pathophysiology of Locus Ceruleus Neurons in a Mouse Model of Rett Syndrome , 2009, The Journal of Neuroscience.

[71]  S. Nelson,et al.  Intact Long-Term Potentiation but Reduced Connectivity between Neocortical Layer 5 Pyramidal Neurons in a Mouse Model of Rett Syndrome , 2009, The Journal of Neuroscience.

[72]  J. Ramirez,et al.  Respiratory Physiology & Neurobiology Breathing Disorders in Rett Syndrome: Progressive Neurochemical Dysfunction in the Respiratory Network after Birth , 2022 .

[73]  S. Kudo,et al.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations , 2009, Neurobiology of Disease.

[74]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  N. Heintz,et al.  The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain , 2009, Science.

[76]  Christina Thaller,et al.  Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus , 2009, Human molecular genetics.

[77]  W. O'Brien,et al.  A Study of the Treatment of Rett Syndrome With Folate and Betaine , 2009, Journal of child neurology.

[78]  A. Ormazabal,et al.  Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment , 2009, Brain and Development.

[79]  Michael E Greenberg,et al.  Communication between the synapse and the nucleus in neuronal development, plasticity, and disease. , 2008, Annual review of cell and developmental biology.

[80]  L. Ricceri,et al.  Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches , 2008, Behavioural pharmacology.

[81]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[82]  H. Zoghbi,et al.  Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome , 2008, Neurology.

[83]  J. H. van der Lee,et al.  Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. , 2008, Journal of clinical epidemiology.

[84]  Liang Zhang,et al.  The MeCP2‐null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability , 2008, Hippocampus.

[85]  J. Seamans,et al.  Losing inhibition with ketamine. , 2008, Nature chemical biology.

[86]  Huda Y. Zoghbi,et al.  The Story of Rett Syndrome: From Clinic to Neurobiology , 2007, Neuron.

[87]  A. Bird,et al.  Reversal of Neurological Defects in a Mouse Model of Rett Syndrome , 2007, Science.

[88]  Ankita Patel,et al.  Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males , 2006, Genetics in Medicine.

[89]  Carol Bower,et al.  Rett syndrome in Australia: a review of the epidemiology. , 2006, The Journal of pediatrics.

[90]  J. Gécz,et al.  Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. , 2005, American journal of human genetics.

[91]  Rudolf Jaenisch,et al.  Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[92]  K. Hameister,et al.  Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome , 2005, Journal of Medical Genetics.

[93]  R. Jaenisch,et al.  Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[94]  W. Brannath,et al.  The advantages and disadvantages of adaptive designs for clinical trials. , 2004, Drug discovery today.

[95]  M. Johnston,et al.  Neurobiology of Rett Syndrome , 2003, Journal of child neurology.

[96]  T. W. Bailey,et al.  Ketamine Differentially Blocks Sensory Afferent Synaptic Transmission in Medial Nucleus Tractus Solitarius (mNTS) , 2003, Anesthesiology.

[97]  J. Christodoulou,et al.  Medium-term open label trial of L-carnitine in Rett syndrome , 2001, Brain and Development.

[98]  E. Monrós,et al.  Rett syndrome in Spain: mutation analysis and clinical correlations , 2001, Brain and Development.

[99]  E. Ballestar,et al.  Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. , 2000, Biochemistry.

[100]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[101]  M. Johnston,et al.  Development of amino acid receptors in frontal cortex from girls with Rett syndrome , 1999, Annals of neurology.

[102]  J. Christodoulou,et al.  Rett Syndrome: Randomized Controlled Trial of L-Carnitine , 1999, Journal of child neurology.

[103]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[104]  A. Bird,et al.  MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin , 1997, Cell.

[105]  J. Frost,et al.  Rett syndrome: Controlled study of an oral opiate antagonist, naltrexone , 1994, Annals of neurology.

[106]  A. Bird,et al.  Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. , 1993, Nucleic acids research.

[107]  A. Bird,et al.  Purification, sequence, and cellular localization of a novel chromosomal protein that binds to Methylated DNA , 1992, Cell.

[108]  H. Moser,et al.  Altered neurochemical markers in Rett's syndrome , 1991, Neurology.

[109]  M. Zappella.  A double blind trial of bromocriptine in the Rett syndrome , 1990, Brain and Development.

[110]  A Rett,et al.  [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. , 1966, Wiener medizinische Wochenschrift.

[111]  H. Hundley,et al.  To edit or not to edit: regulation of ADAR editing specificity and efficiency , 2016, Wiley interdisciplinary reviews. RNA.

[112]  S. Cobb,et al.  Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  A. Percy,et al.  Recent Progress in Rett Syndrome and MeCP2 Dysfunction: Assessment of Potential Treatment Options. , 2013, Future neurology.

[114]  Wolfgang Köpcke,et al.  Clinical trials and rare diseases. , 2010, Advances in experimental medicine and biology.

[115]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[116]  Jan-Fang Cheng,et al.  Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome , 2005, Nature Genetics.

[117]  A. Bird,et al.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). , 2004, Nucleic acids research.

[118]  Rachel A. Horowitz-Scherer,et al.  Chromatin Compaction by Human MeCP2 ASSEMBLY OF NOVEL SECONDARY CHROMATIN STRUCTURES IN THE ABSENCE OF DNA METHYLATION* , 2003 .

[119]  B. Hagberg.  Clinical manifestations and stages of Rett syndrome. , 2002, Mental retardation and developmental disabilities research reviews.

[120]  D. Armstrong.  Neuropathology of Rett syndrome. , 2002, Mental retardation and developmental disabilities research reviews.

[121]  P. M. Fitzgerald,et al.  Rett syndrome and associated movement disorders , 1990, Movement disorders : official journal of the Movement Disorder Society.

[122]  D. Trauner,et al.  Therapeutic effects of a ketogenic diet in Rett syndrome. , 1986, American journal of medical genetics. Supplement.